As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more and more cases linking them to severe eye conditions. In a new study published in the journal JAMA Ophthalmology, University of Utah researchers detailed the stories of several people who took either semaglutide (the active ingredient in Novo Nordisk's Ozempic and Wegovy) or tirzepatide (the active ingredient in Eli Lilly's Mounjaro and Zepbound) who developed eye conditions that can lead to blindness. Led by Utah ophthalmologist and professor Bradley Katz, the researchers looked into the cases of nine people — seven who'd developed the "eye stroke" […]